Abstract
This prospective randomized study compared the efficacy and toxicity of granisetron and dexamethasone to those of granisetron alone for antiemetic control in patients receiving high-dose chemotherapy with or without total body irradiation (TBI) for stem cell transplantation. Patients were divided randomly into 2 groups. Groups received granisetron twice daily at a dose of 40 µg/kg with or without 4 mg dexamethasone (GS group and G group, respectively), starting 30 minutes before each dose of chemotherapeutic agent or TBI, or 12 hours after the first dose if TBI or a drug was given once a day. Fifty patients were evaluated for the analysis. During the first 24 hours of conditioning, 23 of 25 patients (92.0%) in the GS group achieved complete control of emesis (no emetic episodes over the course of a day), compared with 72.0% in the G group (P = .06). For patients receiving TBI on the first day of conditioning, complete emetic control was achieved in all patients (100.0%) in the GS group, compared with 63.2% in the G group (P = .02). The same degree of emetic control was maintained throughout the conditioning period in 38.8% of the GS group and 29.9% of the G group (P = .10). Adverse reactions were observed more frequently in the GS group (68.0% versus 5.0% in the G group). These reactions included insomnia, headache, flushing, and hyperglycemia. None of the events were serious. We conclude that granisetron with dexamethasone seems superior to granisetron alone for the prevention of emesis resulting from the conditioning regimen; however, the more frequent side effects may limit the wide use of this combination.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hesketh PJ, Murphy WK, Lester EP, et al. GR 38032F (GR-C507/ 75): a novel compound effective in the prevention of acute cis- platin-induced emesis.J Clin Oncol. 1989;7:700–705.
Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlor- promazine plus dexamethasone in the treatment of cytostatic- induced emesis: the Granisetron Study Group.Eur J Cancer. 1990; 26(suppl 1):S28-S32.
Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high- dose cisplatin.J Clin Oncol. 1994;12:2204–2210.
Hunter AE, Prentice HG, Pothecary K, et al. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.Bone Marrow Transplant. 1991;7:439–441.
Okamoto S, Takahashi S, Tanosaki R, et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.Bone Marrow Transplant. 1996;17:679–683.
Slavin S, Nagler A, Naparstek E, et al. Nonmyeloaberative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91:756–763.
Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonmyeloablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancy.J Clin Oncol. 1998;16: 2817–2824.
Grigg A, Bardy P, Byron K, et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.Bone Marrow Transplant. 1999;23:107–110.
Heron JF, Goedhals L, Jordaan JP, et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis: the Granisetron Study Group.Ann Oncol. 1994;5:579–584.
Bosi A, Guidi S, Messori A, et al. Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study.J Chemother. 1993;5: 191–196.
Stephens SH, Silvey VL, Wheeler RH. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin.Cancer. 1990;66:443–446.
Ioannidis PA, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta- analysis of randomized evidence.J Clin Oncol. 2000;18:3409–3422.
Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation.Bone Marrow Transplant. 2000;25:1279–1283.
Chao NJ. Graft-versus-host disease: the viewpoint from the donor T cell.Biol Blood Marrow Transplant. 1997;3:1–10.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Matsuoka, S., Okamoto, S., Watanabe, R. et al. Granisetron Plus Dexamethasone Versus Granisetron Alone in the Prevention of Vomiting Induced by Conditioning for Stem Cell Transplantation: A prospective Randomized Study. Int J Hematol 77, 86–90 (2003). https://doi.org/10.1007/BF02982608
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02982608